Cambium Bio Ltd (CMB) - Total Liabilities

Latest as of June 2025: AU$1.46 Million AUD ≈ $1.03 Million USD

Based on the latest financial reports, Cambium Bio Ltd (CMB) has total liabilities worth AU$1.46 Million AUD (≈ $1.03 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Cambium Bio Ltd - Total Liabilities Trend (1999–2025)

This chart illustrates how Cambium Bio Ltd's total liabilities have evolved over time, based on quarterly financial data. See CMB current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Cambium Bio Ltd Competitors by Total Liabilities

The table below lists competitors of Cambium Bio Ltd ranked by their total liabilities.

Company Country Total Liabilities
Pets at Home Group Plc
LSE:PETS
UK GBX681.60 Million
Phoenix Motor Inc. Common Stock
NASDAQ:PEV
USA $48.09 Million
Akkhie Prakarn Public Company Limited
BK:AKP
Thailand ฿97.27 Million
SEKUR PRIVATE DATA LTD.
F:GDT0
Germany €465.42K
Ep&T Global Ltd
AU:EPX
Australia AU$11.52 Million
Resources & Energy Group Ltd
AU:REZ
Australia AU$1.61 Million
Reabold Resources Plc
LSE:RBD
UK GBX2.18 Million
Fiberweb (India) Limited
NSE:FIBERWEB
India Rs166.67 Million

Liability Composition Analysis (1999–2025)

This chart breaks down Cambium Bio Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Cambium Bio Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.36 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.79 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.44 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cambium Bio Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cambium Bio Ltd (1999–2025)

The table below shows the annual total liabilities of Cambium Bio Ltd from 1999 to 2025.

Year Total Liabilities Change
2025-06-30 AU$1.46 Million
≈ $1.03 Million
-49.21%
2024-06-30 AU$2.87 Million
≈ $2.03 Million
-35.22%
2023-06-30 AU$4.43 Million
≈ $3.14 Million
+199.65%
2022-06-30 AU$1.48 Million
≈ $1.05 Million
-66.09%
2021-06-30 AU$4.36 Million
≈ $3.09 Million
+18.12%
2020-06-30 AU$3.70 Million
≈ $2.61 Million
-58.61%
2019-06-30 AU$8.93 Million
≈ $6.32 Million
+333.13%
2018-06-30 AU$2.06 Million
≈ $1.46 Million
+93.57%
2017-06-30 AU$1.06 Million
≈ $753.49K
-7.41%
2016-06-30 AU$1.15 Million
≈ $813.75K
-12.02%
2015-06-30 AU$1.31 Million
≈ $924.88K
-33.00%
2014-06-30 AU$1.95 Million
≈ $1.38 Million
-71.69%
2013-06-30 AU$6.89 Million
≈ $4.88 Million
+411.44%
2012-06-30 AU$1.35 Million
≈ $953.52K
+45.97%
2011-06-30 AU$923.21K
≈ $653.23K
+105.16%
2010-06-30 AU$450.00K
≈ $318.40K
-95.34%
2002-06-30 AU$9.67 Million
≈ $6.84 Million
-92.52%
2001-06-30 AU$129.20 Million
≈ $91.42 Million
+0.72%
2000-06-30 AU$128.27 Million
≈ $90.76 Million
-14.97%
1999-06-30 AU$150.86 Million
≈ $106.74 Million
--

About Cambium Bio Ltd

AU:CMB Australia Biotechnology
Market Cap
$9.19 Million
AU$12.98 Million AUD
Market Cap Rank
#27255 Global
#1353 in Australia
Share Price
AU$0.48
Change (1 day)
+14.46%
52-Week Range
AU$0.20 - AU$0.60
All Time High
AU$22.97
About

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing i… Read more